PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2012; 7(6): e39294.
Published online Jun 18, 2012. doi:  10.1371/journal.pone.0039294
PMCID: PMC3377749
Human Solid Tumor Xenografts in Immunodeficient Mice Are Vulnerable to Lymphomagenesis Associated with Epstein-Barr Virus
Kui Chen,#1 Sharif Ahmed,#1 Oyedele Adeyi,2 John E. Dick,1,3,4 and Anand Ghanekar1,5*
1Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
2Department of Pathology, University Health Network, Toronto, Ontario, Canada
3Division of Stem Cell and Developmental Biology, Campbell Family Institute for Cancer Research/Ontario Cancer Institute, Toronto, Ontario, Canada
4Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
5Department of Surgery, University of Toronto, Toronto, Ontario, Canada
Micah Luftig, Editor
Duke University Medical Center, United States of America
#Contributed equally.
* E-mail: anand.ghanekar/at/uhn.ca
Conceived and designed the experiments: KC SA OA JED AG. Performed the experiments: KC SA OA AG. Analyzed the data: KC SA OA JED AG. Contributed reagents/materials/analysis tools: KC SA OA JED AG. Wrote the paper: KC SA OA JED AG.
Received January 26, 2012; Accepted May 22, 2012.
Xenografting primary human solid tumor tissue into immunodeficient mice is a widely used tool in studies of human cancer biology; however, care must be taken to prove that the tumors obtained recapitulate parent tissue. We xenografted primary human hepatocellular carcinoma (HCC) tumor fragments or bulk tumor cell suspensions into immunodeficient mice. We unexpectedly observed that 11 of 21 xenografts generated from 16 independent patient samples resembled lymphoid neoplasms rather than HCC. Immunohistochemistry and flow cytometry analyses revealed that the lymphoid neoplasms were comprised of cells expressing human CD45 and CD19/20, consistent with human B lymphocytes. In situ hybridization was strongly positive for Epstein-Barr virus (EBV) encoded RNA. Genomic analysis revealed unique monoclonal or oligoclonal immunoglobulin heavy chain gene rearrangements in each B-cell neoplasm. These data demonstrate that the lymphoid neoplasms were EBV-associated human B-cell lymphomas. Analogous to EBV-associated lymphoproliferative disorders in immunocompromised humans, the human lymphomas in these HCC xenografts likely developed from reactivation of latent EBV in intratumoral passenger B lymphocytes following their xenotransplantation into immunodeficient recipient mice. Given the high prevalence of latent EBV infection in humans and the universal presence of B lymphocytes in solid tumors, this potentially confounding process represents an important pitfall of human solid tumor xenografting. This phenomenon can be recognized and avoided by routine phenotyping of primary tumors and xenografts with human leukocyte markers, and provides a compelling biological rationale for exclusion of these cells from human solid tumor xenotransplantation assays.
Xenotransplantation of human cancers into immunodeficient mice is very useful for studying human tumor biology [1]. This approach is widely used for research into mechanisms of tumor growth and for preclinical evaluation of anti-cancer therapies [2], [3]. The most commonly utilized mouse strains, such as the non-obese diabetic severe combined immunodeficiency (NOD/SCID) and NOD/SCID/interleukin 2 receptor gamma chain null (NSG) strains, are deficient in both innate and adaptive immunity and thereby permit the survival of human tissue [4], [5].
While it is possible to generate xenografts from purified populations of cells from some human cancers [6][9], many studies describe the implantation of tumor fragments or bulk tumor cell suspensions in mice to maximize the chances of establishing xenografts from limited clinical samples [10][13]. Reports describing xenografts from human hepatocellular carcinoma (HCC), for example, reveal that only 10–20% of clinical samples yielded viable xenografts when dissociated into cell suspensions that were further fractionated for implantation in mice [14], [15].
Epstein-Barr virus (EBV) is a human-restricted herpes virus which infects over 90% of the human population, persisting as a latent infection for the lifetime of the host [16], [17]. EBV preferentially infects B lymphocytes and “transforms” them into a proliferative state by altering cellular gene transcription, constitutively activating key cell-signalling pathways, and preventing apoptosis [18]. In immunocompetent individuals, EBV is well controlled by cellular and humoral immunity, and transformed B cells are continually eliminated because they express foreign antigens. Individuals who are immunocompromised, such as patients with HIV/AIDS or those receiving immunosuppressive drugs following transplantation, are at risk of developing B-cell lymphomas from the uncontrolled proliferation of EBV-transformed cells [17], [19], [20]. Similarly, spontaneous development of EBV-associated human lymphomas has been described in immunodeficient mice repopulated with normal human hematopoietic cells due to reactivation of latent EBV [21].
In our attempts to efficiently generate xenografts from human HCC specimens, we implanted tumor fragments or bulk tumor cell suspensions into immunodeficient mice. To validate our model, we carefully examined xenografts to determine how accurately they recapitulated parent tumors. Unexpectedly, we observed that several xenografts did not resemble HCC, and sought to characterize these tumors further in order to understand potential pitfalls of our xenotransplantation assay. In this report, we describe how our further characterization of these atypical xenografts revealed them to be EBV-associated human B-cell lymphomas and discuss the implications of this observation.
As summarized in Table 1, we obtained fresh HCC samples from 16 consecutive patients who were undergoing surgical resection of their tumors as primary therapy. None of the patients had received any form of neoadjuvant therapy. The diagnosis of HCC and degree of tumor differentiation in each resected specimen was determined through standard diagnostic assessments performed by clinical hepatopathologists at our institution independent of this study. Of 21 xenografts generated from the 16 different HCC specimens, we identified only 10 xenografts that resembled HCC on initial histopathological assessment (“HCC-like xenografts”). The remaining 11 xenografts resembled lymphoid neoplasms rather than HCC (“non-HCC-like xenografts”). In comparing the groups of patient samples that yielded HCC-like xenografts as compared with those that yielded non-HCC-like xenografts, there were no obvious differences between groups in patient age (68±11 years vs. 62±10 years, p = 0.27), underlying liver disease, or degree of differentiation of primary tumors. HCC-like and non-HCC-like xenografts arose in both NOD/SCID and NSG mice, and the time intervals between HCC implantation and harvesting of the first xenografts were similar (180±81 days vs. 144±65 days, p = 0.28).
Table 1
Table 1
Patient demographics, parent HCC grade, and xenograft characteristics.
As shown in Figure 1A, HCC-like xenografts shared many histological features of HCC with parent tumors, including hepatocyte-like cells with nuclear atypia and high nuclear-to-cytoplasmic ratio, absence of portal tracts, and distorted trabeculae with increased thickness of hepatocellular plates. As shown in Figure 1B, non-HCC-like xenografts differed significantly from parent HCC tumors and HCC-like xenografts. Non-HCC-like xenografts had no architectural features of HCC, instead consisting of monomorphic populations of small lymphoid mononuclear cells with nuclear atypia and high mitotic index. As shown in Figure 1C, analysis of xenografts by RT-PCR revealed that HCC-like xenografts retained expression of many liver cell markers, while these were diminished or absent in non-HCC-like xenografts. We suspect that the persistent detection of liver epithelial markers such as cytokeratins, AAT and TDO in some non-HCC-like xenografts reflects the extreme sensitivity of RT-PCR to detect the presence of some persisting HCC cells in non-HCC-like xenografts despite near replacement of the originally implanted HCC tissue by rapidly proliferating lymphoid cells.
Figure 1
Figure 1
Xenografts arising from human HCC specimens.
Due to the resemblance of non-HCC-like xenografts to lymphoid neoplasms, we evaluated the expression of human and murine leukocyte markers by immunohistochemistry. In contrast to the typically sparse distribution of leukocytes observed in all of the parent human HCC tissues to a similar extent mainly along portal tracts when they were invaded by the tumor (Figure 2A), non-HCC-like xenografts were densely infiltrated or replaced by cells that could be characterized as human B lymphocytes by their expression of human CD45 and CD20 (Figure 2B). Flow cytometry confirmed that the human CD45+ population consisted predominantly of CD19+ cells, consistent with human B lymphocytes (Figure 2C). Staining for the human T-cell antigen CD3 was minimal, as was staining for the mouse lymphocyte antigen B220 and the mouse histocompatibility antigen H2k (data not shown). We did not identify any correlation between leukocyte infiltration in parent HCC tissues and the development of non-HCC-like xenografts. In addition, prior to their HCC resection, none of the source patients had a history of lymphoproliferative disease or an immunodeficient state known to predispose to lymphoproliferative disorders (eg. human immunodeficiency virus infection, pharmacological immunosuppression).
Figure 2
Figure 2
Expression of leukocyte markers and EBER in non-HCC-like xenografts.
Cognizant of the importance of EBV in the pathogenesis of lymphoproliferative disorders in immunocompromised humans [18], we evaluated our xenografts for evidence of EBV infection by in situ hybridization (ISH) for EBV-encoded RNA (EBER), and found that this was strongly positive in the B lymphocytes populating the non-HCC-like xenografts (Figure 2B). We were unable to determine the presence or absence of latent EBV in parent HCC specimens using EBER ISH and PCR for EBV DNA, and this needs to be prospectively evaluated. Since EBV is so effectively suppressed in immunocompetent humans, we suspect that the tiny amount of EBER and EBV DNA that would be present in a few B-cells in the source tumor, of which we had extremely limited histological sections for retrospective analysis, was below the detection threshold of our assays. Preoperative EBV serology of source patients was not available since this is not routinely tested.
To further characterize the non-HCC-like xenografts, we evaluated the clonality of the human B lymphocyte proliferations by assaying immunoglobulin heavy chain (IgH) gene rearrangements. As shown in Figure 3, B-cell proliferations arose from a single clone in 10 of 11 non-HCC-like xenografts, and from two clones in the remaining case. In two instances, independent xenografts obtained from separate fragments of a single parent HCC developed into lymphoid tumors that demonstrated different IgH rearrangements. This suggests that the malignant transformation and clonal expansion responsible for the EBV-associated lymphomas observed in this study occurred subsequent to the xenotransplantation of human tissue into immunodeficient mice, and that lymphomas were not already present in source tissues.
Figure 3
Figure 3
Immunoglobulin heavy chain gene rearrangements in non-HCC-like xenografts.
To exclude contamination by a lymphocyte cell line or cross-contamination between xenografts as a source of the lymphomas, we performed short tandem repeat (STR) analysis on genomic DNA from each xenograft and confirmed that xenografts from different patients were genetically distinct (Table 2).
Table 2
Table 2
Short tandem repeat (STR) analysis demonstrating unique genetic identity of each xenograft.
Collectively, these findings demonstrate that non-HCC-like xenografts were comprised of EBV-associated human B-cell lymphomas that had developed spontaneously from xenografted human HCC tissues. Analogous to EBV-associated lymphoproliferative disorders in immunocompromised humans, this likely occurred through reactivation of latent EBV and malignant transformation of intratumoral passenger B lymphocytes made possible by the immunodeficiency of the recipient mice. In future work, we plan to apply cell sorting techniques to exclude CD45+ cells from human HCC samples prior to xenotransplantation in order to prevent this process.
The phenomenon of EBV-associated lymphomagenesis has not been reported in the context of human solid tumor xenografts. Considering the high prevalence of latent EBV in humans [16] and the presence of B lymphocytes in solid tumors from all human tissues [22], it is likely that most solid tumors would be vulnerable to this process. It is unlikely that this phenomenon is unique to HCC, as EBV has not been implicated in the pathogenesis of human HCC [23], primary hepatic lymphoid malignancies are very rare [24], and there is no clearly established causative link between chronic liver disease and the incidence of lymphoproliferative disease. We thus believe that our observations are of importance to all investigators utilizing human solid tumor xenotransplantation assays. As we have shown, lymphomas can arise within the first xenografts obtained, and do not require serial tumor passaging. Unrecognized, this process may confound experimental data such as measures of tumor growth and markers of tumor cell populations. Lymphomas may also competitively eliminate the tumor tissue of interest, resulting in loss of valuable samples.
This process can best be recognized through phenotyping of xenografted tissues using leukocyte markers. Histopathological assessment is not sufficient, as lymphomas may be misinterpreted as poorly differentiated epithelial tumors. Initial growth kinetics of lymphomas in our model was similar to HCC-like xenografts, indicating that this process cannot be detected by gross observations alone. Because lymphomas may arise from one or two B-cell clones, immunomagnetic depletion of CD45+ cells may not be sufficient to prevent this process since all CD45+ cells are not removed [25]. Flow cytometry-based single-cell sorting is the most stringent technique to identify and eliminate human leukocytes from solid tumor xenotransplantation assays. Most rigorous analyses of human solid cancer xenografts incorporate routine quantification, exclusion or depletion of contaminating CD45+ cells from assays targeting biological and functional properties of specific subpopulations of tumor cells [26]; our observations provide a compelling biological rationale to support this practice and extend it to include all observations involving solid tumor xenografts.
It is important to note that the generalizability of our observations should be interpreted with caution in the context of a relatively small sample size of patients, HCC specimens, and xenografts. The clinical characteristics of the source patients are observational only and were retrospectively analyzed, making this study vulnerable to potentially confounding patient factors or differences that it is underpowered to detect. Similarly, although our data does not demonstrate any obvious relationships between the xenografting methods used (eg. tumor fragment vs. cell suspension, NSG vs. NOD/SCID mouse strain) and the development of EBV-associated lymphomas, the study is underpowered to detect the relative influence of these variables on the results.
In summary, we have shown that human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with EBV. This potentially confounding process can be recognized through immunophenotyping of xenografts using leukocyte markers and should be preventable by excluding leukocytes from source tissues. This phenomenon should be recognized as an important pitfall of human solid tumor xenotransplantation assays.
Ethics statement
Ethical approvals were obtained from the University Health Network Research Ethics Board (Protocol #08-0697-TE) and Animal Care Committee (Animal Use Protocol #1595). Human tissues were obtained with written consent from source patients.
Patient samples
Human HCC samples and demographic data were obtained from patients undergoing surgery and anonymized with 5-digit numbers. Tumor samples were obtained only from patients for whom surgical resection was the primary form of HCC treatment, and who had not received any form of systemic or locoregional neoadjuvant therapy (eg. systemic chemotherapy, intrahepatic chemotherapy, radiofrequency tumor ablation, external beam radiation therapy). Fresh surgical resection specimens were transferred from the operating room to the surgical pathology suite within 15 minutes of removal from the patient and promptly sectioned by the attending clinical pathologist. Samples for xenografting were taken from the peripheral zone of the tumor in all cases, and appeared grossly viable and non-necrotic. Samples were placed in serum-free Dulbecco's Modified Eagle Medium (DMEM, Life Technologies) at 4 degrees Celsius and transferred to the research laboratory for immediate processing and implantation into recipient mice. HCC diagnoses were subsequently verified in all cases using clinical pathology reports issued independent of this study.
Xenografts
Bulk tumor cell suspensions were prepared by digestion with Type IV Collagenase (Sigma) for 30–60 minutes at 37°C, passage through a 70 µm cell strainer (BD Biosciences) and lysis of red blood cells using RBC lysis buffer (eBioscience). Following trypan blue analysis, 106 viable cells were resuspended in 50 µl of Matrigel (BD Biosciences) and injected subcutaneously with a 25 gauge needle into the flanks of anesthetized NOD/SCID or NSG mice. No attempt was made to separate HCC cells from other cell populations within tumor samples. Alternatively, 3 mm3 tumor fragments in Matrigel were implanted subcutaneously on the flanks through a 5 mm skin incision. Priority was given to implantation of tumor fragments; bulk cell suspensions were injected if sufficient tumor tissue was available and if the fraction of viable cells in the tumor cell suspension exceeded 70%.
RT-PCR
RNA was isolated using TRIZOL Reagent (Life Technologies) and reverse-transcribed using SuperScript First-Strand Synthesis System (Invitrogen). PCR was performed with Taq DNA Polymerase (New England Biolabs) using conventional thermocycling protocols. Amplified products were visualized with ethidium bromide agarose gel electrophoresis. Primer sets were synthesized based on publicly available human nucleotide sequences (see Table S1).
Histopathology
Formalin-fixed, paraffin-embedded tissues were utilized. For immunohistochemistry, de-waxed sections were blocked with 3% hydrogen peroxide, avidin/biotin blocking kit (Vector Labs), and 10% normal serum from the secondary Ab species, then incubated at room temperature with primary Ab for 1 hour as follows: mouse anti-human CD45 (1[ratio]80, Dako), mouse anti-human CD20 (1[ratio]100, Dako), rabbit anti-human CD3 (1[ratio]300, Dako), or rat anti-mouse B220 (1[ratio]1000, BD Biosciences). This was followed by biotin labeled secondary Ab (Vector Labs) for 30 minutes and HRP-conjugated ultrastreptavidin labeling reagent (ID Labs) for 30 minutes. Color was developed with DAB solution (Dako). Sections were counterstained with Mayer's hematoxylin, dehydrated and mounted in Permount (Fisher). In situ hybridization for EBER was performed on a Ventana Medical Systems automated slide stainer employing EBER probes and the Ventana ISH iVIEW Blue Detection Kit according to manufacturer instructions.
Flow cytometry
Cells were blocked in PBS containing 0.5% BSA and human FcR Blocking Reagent (Miltenyi Biotec), then incubated with anti-mouse H2-K [d] FITC (SF1-1.1, BD Biosciences), anti-human CD45 PE-Cy7 (HI30, BD Biosciences), anti-human CD3 Alexa Fluor 647 (UCHT1, BioLegend) and anti-human CD19 PE (HIB19, BioLegend), or with FITC Mouse IgG2a, κ (G155-178, BD Biosciences), PE-Cy7 Mouse IgG1, κ (MOPC-21, BD Biosciences), Alexa Fluor 647 Mouse IgG1, κ (MOPC-21, BD Biosciences) and PE Mouse IgG1, κ (MOPC-21, BD Biosciences) isotype controls. After washing, cells were incubated with Live/Dead Fixable Violet Dead Cell Stain Kit (Invitrogen) and analyzed using LSR II Flow Cytometer (BD Biosciences) with FlowJo V8.8.6.
IgH gene rearrangement assay
DNA was isolated using GenElute Mammalian Genomic DNA Miniprep Kit (Sigma). Clonality was evaluated by PCR for VDJ rearrangement of the IgH gene using primers directed at framework three of the V segments (IgHV: ACACGGCC(A/C/G)TGTATTACTGT) and J segments (IgHJ: TGAGGAGACGGTGACC), flanking the hypervariable gene region. PCR was performed with Taq DNA Polymerase (New England Biolabs) and conventional thermocycling protocols. Amplified fragments were visualized with ethidium bromide agarose gel electrophoresis. Clonality was determined by the number of dominant bands, and bands of unique size were interpreted as products of distinct B-cell clones.
STR analysis
Genotyping was performed using the AmpFlSTR Identifiler PCR Amplification Kit (Life Technologies) that employs a multiplex assay which amplifies 15 tetranucleotide repeat loci and the Amelogenin gender determining marker. Samples were run on an ABI 3100 Genetic Analyzer and analyzed in GeneMapper v3.7.
Statistical analysis
Where applicable, unpaired t-tests were used to compare means between two groups and statistical significance was expressed with two-tailed P values.
Supporting Information
Table S1
PCR primer sets.
(DOC)
Footnotes
Competing Interests: The authors have declared that no competing interests exist.
Funding: Supported in part by a Canadian Institutes of Health Research (www.cihr.ca) Phase 1 Clinician-Scientist Award (AG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.
1. Jin K, Teng L, Shen Y, He K, Xu Z, et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol. 2010;12:473–480. [PubMed]
2. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006;66:3351–3354, discussion 3354. [PubMed]
3. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313–319. [PubMed]
4. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154:180–191. [PubMed]
5. Ohbo K, Suda T, Hashiyama M, Mantani A, Ikebe M, et al. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood. 1996;87:956–967. [PubMed]
6. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–110. [PubMed]
7. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593–598. [PMC free article] [PubMed]
8. Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J, et al. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell. 2010;7:279–282. [PMC free article] [PubMed]
9. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401. [PubMed]
10. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008;14:6456–6468. [PubMed]
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988. [PubMed]
12. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, et al. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009;4:1670–1680. [PubMed]
13. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007;2:247–250. [PubMed]
14. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13:153–166. [PubMed]
15. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 2011;7:694–707. [PubMed]
16. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481–492. [PubMed]
17. Vereide D, Sugden B. Insights into the evolution of lymphomas induced by Epstein-Barr virus. Adv Cancer Res. 2010;108:1–19. [PubMed]
18. Birx DL, Redfield RR, Tosato G. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med. 1986;314:874–879. [PubMed]
19. Allen U, Preiksaitis J. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant. 2009;9:S87–96. [PubMed]
20. Mosier DE, Picchio GR, Baird SM, Kobayashi R, Kipps TJ. Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes. Cancer Res. 1992;52:5552s–5553s. [PubMed]
21. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4:757–768. [PubMed]
22. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185:4977–4982. [PubMed]
23. Petrova M, Kamburov V. Epstein-Barr virus: silent companion or causative agent of chronic liver disease? World J Gastroenterol. 2010;16:4130–4134. [PMC free article] [PubMed]
24. Utsunomiya T, Okamoto M, Tsujita E, Yamamoto M, Tsutsui S, et al. Hepatocellular carcinoma infiltrated with non-Hodgkin's lymphoma: report of a case. Surg Today. 2009;39:1010–1012. [PubMed]
25. Dainiak MB, Kumar A, Galaev IY, Mattiasson B. Methods in cell separations. Adv Biochem Eng Biotechnol. 2007;106:1–18. [PubMed]
26. Visvader JE. Cells of origin in cancer. Nature. 2011;469:314–322. [PubMed]
Articles from PLoS ONE are provided here courtesy of
Public Library of Science